169 related articles for article (PubMed ID: 30339905)
1. Tumor targeted genome editing mediated by a multi-functional gene vector for regulating cell behaviors.
Liu BY; He XY; Zhuo RX; Cheng SX
J Control Release; 2018 Dec; 291():90-98. PubMed ID: 30339905
[TBL] [Abstract][Full Text] [Related]
2. A Dual-Targeting Delivery System for Effective Genome Editing and In Situ Detecting Related Protein Expression in Edited Cells.
Liu BY; He XY; Xu C; Xu L; Ai SL; Cheng SX; Zhuo RX
Biomacromolecules; 2018 Jul; 19(7):2957-2968. PubMed ID: 29617556
[TBL] [Abstract][Full Text] [Related]
3. Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Liu BY; He XY; Zhuo RX; Cheng SX
Nanoscale; 2018 Dec; 10(45):21209-21218. PubMed ID: 30417194
[TBL] [Abstract][Full Text] [Related]
4. Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Liu BY; He XY; Xu C; Ren XH; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jul; 11(27):23870-23879. PubMed ID: 31257851
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional Vector for Delivery of Genome Editing Plasmid Targeting β-Catenin to Remodulate Cancer Cell Properties.
He XY; Liu BY; Peng Y; Zhuo RX; Cheng SX
ACS Appl Mater Interfaces; 2019 Jan; 11(1):226-237. PubMed ID: 30540162
[TBL] [Abstract][Full Text] [Related]
6. Aptamer/Peptide-Functionalized Genome-Editing System for Effective Immune Restoration through Reversal of PD-L1-Mediated Cancer Immunosuppression.
He XY; Ren XH; Peng Y; Zhang JP; Ai SL; Liu BY; Xu C; Cheng SX
Adv Mater; 2020 Apr; 32(17):e2000208. PubMed ID: 32147886
[TBL] [Abstract][Full Text] [Related]
7. Self-Assembled Plasmid Delivery System for PPM1D Knockout to Reverse Tumor Malignancy.
Ren XH; He XY; Liu BY; Xu C; Cheng SX
ACS Appl Bio Mater; 2020 Nov; 3(11):7831-7839. PubMed ID: 35019523
[TBL] [Abstract][Full Text] [Related]
8. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
9. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
[TBL] [Abstract][Full Text] [Related]
10. Nonviral gene editing via CRISPR/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide.
Wang HX; Song Z; Lao YH; Xu X; Gong J; Cheng D; Chakraborty S; Park JS; Li M; Huang D; Yin L; Cheng J; Leong KW
Proc Natl Acad Sci U S A; 2018 May; 115(19):4903-4908. PubMed ID: 29686087
[TBL] [Abstract][Full Text] [Related]
11. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
12. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene.
Ma K; Li W; Zhu G; Sun S; Chi H; Yin Y; Diao H; Xing XJ; Guo Z; Wang L; Xu W; Cui C; Xu J
Biomed Pharmacother; 2021 Oct; 142():112061. PubMed ID: 34449313
[TBL] [Abstract][Full Text] [Related]
13. Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid.
Tang Q; Liu J; Jiang Y; Zhang M; Mao L; Wang M
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46585-46590. PubMed ID: 31763806
[TBL] [Abstract][Full Text] [Related]
14. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
16. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy.
Ren XH; Xu C; Li LL; Zuo Y; Han D; He XY; Cheng SX
J Control Release; 2022 Mar; 343():645-656. PubMed ID: 35157940
[TBL] [Abstract][Full Text] [Related]
17. A Photolabile Semiconducting Polymer Nanotransducer for Near-Infrared Regulation of CRISPR/Cas9 Gene Editing.
Lyu Y; He S; Li J; Jiang Y; Sun H; Miao Y; Pu K
Angew Chem Int Ed Engl; 2019 Dec; 58(50):18197-18201. PubMed ID: 31566854
[TBL] [Abstract][Full Text] [Related]
18. Short cell-penetration peptide conjugated bioreducible polymer enhances gene editing of CRISPR system.
Wang X; Cai C; Lv W; Chen K; Li J; Liao K; Zhang Y; Huang H; Lin Y; Rong Z; Duan X
J Nanobiotechnology; 2024 May; 22(1):284. PubMed ID: 38790037
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the native type I-B CRISPR-Cas for genome editing in a polyploid archaeon.
Cheng F; Gong L; Zhao D; Yang H; Zhou J; Li M; Xiang H
J Genet Genomics; 2017 Nov; 44(11):541-548. PubMed ID: 29169919
[TBL] [Abstract][Full Text] [Related]
20. Non-viral delivery of genome-editing nucleases for gene therapy.
Wang M; Glass ZA; Xu Q
Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
